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Abstract:Methamphetamineuse inAustralia has recently attractedconsiderable attentiondue to increasedhu-
man and social costs. Despite evidences indicating increasingmethamphetamine-related harm and significant
numbers of frequent and dependent users, methamphetamine treatment coverage remains low in Australia.
This paper aims to investigate the complex interplay between methamphetamine use and treatment-related
access by designing an agent-based model, using epidemiological data and expert-derived assumptions. This
paper presents the architecture and core mechanisms of an agent-based model, TreatMethHarm, and details
the results of model calibration performed by testing the key model parameters. At this stage of development,
TreatMethHarm is able to produce proportions of methamphetamine users that replicate those produced by
our epidemiological survey. However, this agent-basedmodel still requires additional information and further
tests before validation. TreatMethHarm provides a useful tool to elicit dialogue between researchers from dif-
ferent disciplines, integrate a variety of data and identify missing information.
Keywords: Agent-Based Modelling, Methamphetamine Use, Drug-Related Harms, Treatment Access, Drug Ca-
reer
Introduction
1.1 Social simulationmethods have recently been applied to substance use phenomena through the development
of agent-basedmodels (Perez et al. 2005;Gormanet al. 2006; Lamyet al. 2011;Hoer et al. 2012; Perez et al. 2012;
Bobashev et al. 2014; Lamy et al. 2015). This type of simulation allows researchers to embed characteristics of
research participants into virtual entities (called ’agents’) and to recreate their trajectories of drug engagement
inside an artificial society. In this virtual context, agents interact with their environment and other agents in
an autonomous and dynamic way (Wooldridge et al. 1995; Feber 1998; Gilbert 2008). These models provide
the capacity to examine how changes in key factors related to substance use (e.g., public policies, drugmarket
characteristics) shape the substance use and related ‘trajectories’ of agents allowing simulation of the eects
of these changes in real life.
1.2 In this study we developed an agent-basedmodel of key aspects of methamphetamine use in Melbourne, Aus-
tralia’s second largest city, and how these shape experience of harms and use of treatment services. Metham-
phetamine (methylamphetamine) is a synthetic psychostimulant that can produce a wide range of eects val-
ued by the drug’s consumers, including euphoria, enhanced self-confidence and increased alertnesswhen con-
sumed (Feldman et al. 1997). However, use of the drug has also been associated with a range of physical (e.g.,
teeth grinding, cardiac arrhythmia, stroke) and psychological (acute psychosis, depression and anxiety) harms
(Julien et al. 2008). These adverse consequences appear gradually as the results of iterated usages and can un-
derpin individuals’ motivations for accessing treatment (Quinn et al. 2013a). In this context, this study’s simula-
tion aimed to reproduce trajectories ofmethamphetamine use and identify elements shaping such trajectories
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tomore comprehensively investigate utilisation of drug treatment bymethamphetamine users over time. With
these trajectoriesweremodelled, the final goal of this researchwas to identify the diiculties (i.e., barriers) that
methamphetamine users searching for treatment can experience and to assess innovative and evidence-based
strategies to improve their access to relevant treatment services.
1.3 Surveys suggest that, aer cannabis, methamphetamine is the secondmost frequently used illicit drug in Aus-
tralia with an estimated 2.1% of the Australian population above 14 years old reporting past-year use of the
drug (AIHW2014). This figure has remained relatively stable since 2007 and includes thosewhomay report only
infrequent use of the drug (Lim et al. 2015). The precise number of people who use methamphetamine (here-
aer termed ’methamphetamine users’) and experience problems is unknown, but McKetin and colleagues es-
timated that there were 102,000 ‘dependent’ and/or ‘regular’ methamphetamine users in 2002/2003 (McKetin
et al. 2005). However, few of these people receive treatment for their use in a given year (Quinn et al. 2013b).
1.4 Despite this relative stability in population-level estimates of use, indices of methamphetamine-related harms
have been increasing in parts of Australia. For example, increases in both the number of methamphetamine-
related ambulance attendances and treatment episodes have been documented in Victoria (Hellbroon et al.
2013). In themainstreammedia these increases have typically beenattributed to escalating use among the gen-
eral population (Limet al. 2015), but recent research suggests that they have occurred in the context of dramatic
changes in the methamphetamine market, in which a sharp decline in the purity-adjusted price of the drug
has been observed (Scott et al. 2015). These market changes may underpin the increased methamphetamine-
related harms that have been observed in Victoria; in this context, the concurrent rise in methamphetamine-
related treatment episodes is unsurprising given previous research which indicated that treatment utilisation
is associated with greater experience of methamphetamine-related consequences (Quinn et al. 2013a).
1.5 This paper describes the development of TreatMethHarm, an agent-based model of methamphetamine use
and related service utilisation that draws on data collected during the course of a wider project conducted in
Melbourne during 2009-2012. This wider project collected both qualitative (Du & Moore 2014) and quantita-
tive/epidemiologic data that were used to develop and parameterise the key features of the model. In the first
section we describe the conceptual model and its principal components; the second section presents the cali-
bration of the model by testing key model parameters and shows the evolution of our population of metham-
phetamine users; lastly, the third section discusses the outcomes and limitations of TreatMethHarm in its final
form, and the potential for its future use in modelling policy scenarios.
Modelling Methamphetamine Use and Access to Treatment
2.1 The two main objectives of the conceptual model are to reproduce (1) the evolution of a known population of
methamphetamine users and (2) their access to service structures that can provide treatment or referral into
treatment. The work was underpinned by the epidemiological data collected during the baseline and follow-
up surveys of regular (at least monthly) methamphetamine users conducted for the wider study (Quinn et al.
2013a,b).
2.2 Atabasic level, thesedata indicated thatall participants reporteduseofadditionaldrugs (e.g., cannabis, heroin,
alcohol). Further, 62% were classified as ‘methamphetamine-dependent’ according to the Severity of Depen-
dence Scale (SDS) and almost 60% reporting injecting the drug at baseline. A large minority (41%) of partici-
pants could be described as ‘service-avoiders’ (i.e., they considered any form of treatment or support service
to be unnecessary), while 59% were described as ‘service-inclined’ (i.e., participants who described their use
as problematic or harmful).
2.3 In TreatMethHarm, each agent or user represents a methamphetamine user characterised by a set of individ-
ual attributes. The two most important attributes are Stage of use (defined by frequency of consumption and
other drug use patterns) and health attributes (defined through parameters related to agents’ overall physical
and psychological states). Users also display a set of ‘belief’ attributes characterising the opinions users have
of methamphetamine and related treatment services. These dierent beliefs underpin the decisions agents
make concerning their consumption and choices regarding both treatment and referral mechanisms (e.g., po-
lice, general practitioners (GPs), social services).
2.4 In addition to their attributes, users are part of a social network of users randomly chosen from the popula-
tion. In the model, networks shape the judgment and actions of their members (see below). Furthermore,
TreatMethHarmdisplays a range of locations representing the dierent support services and settings that users
might access throughout their career. The next section presents the main components shaping the trajectory
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of users in TreatMethHarm and how changes in agent trajectories can in turn aect their own choices as well as
the actions of other agents.
Stages of methamphetamine use
2.5 The trajectory of a given methamphetamine user was modelled within a hierarchy of four use ‘stages’ defined
by frequency of use and a related set of practices (Becker 1953; Abbott 2001). The data collected during the
epidemiological survey suggested three main stages of methamphetamine use within the cohort:
• Occasional users (stage 1 or S1) — users who consume methamphetamine less than twice a week and
smoke or snort it;
• Frequent users (stage 2 or S2) — users who consumemethamphetamine at least three times a week;
• Problematic users (stage3or S3)— individualswithdaily or almostdailymethamphetamine consumption
and inject drugs
2.6 These three stages and their related frequency of use are implemented in the model as attributes. TreatMeth-
Harm also includes users at S0, who are potential ‘experimenters’ or previous users (who can return to use). S0
agents smoke/snort methamphetamine and use methamphetamine infrequently (less than weekly).
2.7 One factor shaping the trajectory of methamphetamine users is tolerance. Tolerance of methamphetamine-
related eects results from regular and repeated use; as tolerance increases, users consume more of the sub-
stance (Feldman et al. 1997) and/or will switch to other routes of administration in order to obtain the desired
eects (consistent with the high frequency of use among Australian methamphetamine users in the context of
escalating drug purity (AIHW 2014; Scott et al. 2015). Higher consumption as well as more harmful methods of
administration increase the risks of adverse health eects, which, in turn, increases the likelihood of seeking
treatment.
2.8 To integrate tolerance in agents’ decision, we created a stage attribute describing the degree of tolerance ex-
perienced by the agents. This attribute defines their frequency of use and aects some of their actions (see
below).
2.9 To capture the gradual development of tolerance in TreatMethHarm, each virtual user remembers its consump-
tion per day (through the memuse-day attribute) and per week (memuse-week attribute). They check their
memuse-week score to evaluate their tolerance and may, in turn, modify their stage attribute weekly, but can-
not move more than one stage per week within the model cycle. This constraint means, for example, that S3
users cannot return to S0 before aminimumof three weeks. Agents, therefore, memorise their consumption of
the past three weeks (through thememuse-week2, memuse-week3 andmemuse-week4 attributes). The stage
dynamic is based on the consumption frequency data drawn from our epidemiological data and is presented
in Figure 1.
2.10 This stage dynamic mainly depends on; (1) the decision to consume, as this determines the frequency of use,
and (2) on the perception of related harms, as this determines the frequency with which users seek support
services. These two processes are presented in the two next subsections.
Decision to consume
2.11 People engage in methamphetamine use for a variety of reasons, including seeking pleasure, avoiding pain
and as part of daily routines (e.g., Newton et al. 2009) with tolerance increasing with frequency of use (Cho &
Melega 2002). In our epidemiological work, most participants reported that ‘pleasure seeking’ (e.g., for sex or
‘fun’) was a primarymotivation formethamphetamine use, alongwith ‘craving’ and ‘out of habit’. Based on our
findings and the relevant literature, methamphetamine use in TreatMethHarm is shaped by pleasure seeking
and growing tolerance.
Pleasure seeking
2.12 Pleasure seeking isaprimarydriverof consumption inTreatMethHarm. Theuser’sdecision toconsumemetham-
phetamine for pleasure is reproduced by the interaction of three main elements: a degree of curiosity toward
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Figure 1: Transition paths between stages.
methamphetamine; the user’s tolerance; and the general acceptance and opinion of the virtual agent popula-
tion.
2.13 The first element, called initialPleasure (iP), represents an agent’s initial interest in the substance. This charac-
teristic is randomly attributed to each user using a normal distribution (µ = 1, σ = 0.4, range [0− 2]) and does
not change during the simulation. A low value of iP defines a low desire formethamphetamine eects, whereas
a high value indicates high interest in its eects. The second element, tolerance, is introduced here to reflect
a gradual adaptation to the eects of the substance. Tolerance is characterised by the stage attribute of the
agent. To calibrate themodel, we introduced a%attempt variable. This value is initially chosen by themodeler
and reflects the global patterns ofmethamphetamine consumption in a given population. The%attempt value
is added to the initialPleasure of users, such that the higher the value of%attempt, the more likely users are to
engage inmethamphetamine use. By integrating these three elements, TreatMethHarmcaptures psychological
and social factors shaping use.
2.14 Nevertheless, if pleasure is themainmotivation to usemethamphetamine, the decision depends ultimately on
the meanings or beliefs that users associate with the substance (Blumer 1998). To represent these meanings,
users are initially assigned a randomly distributed attribute, named meaningMeth, representing the primary
meanings ascribed to methamphetamine (randomised normal distribution with µ = 1, σ = 0.4, and range
[0, 2]). A high value ofmeaningMeth indicates a positivemeaning associatedwith the substance and so a higher
chance of consumption, whereas a low value indicates a decreased probability of consumption. In contrast to
initialPleasure, this value evolves throughout the simulation to allow users to reevaluate the cultural meanings
of methamphetamine on the basis of their own experiences as well as on the basis of their interactions with
other Networkmembers (see below). For example, users could negatively reevaluate the meaning of metham-
phetamine if their physical state deteriorates, if they experience an overdose, or if they observe detrimental
eects of methamphetamine consumption among other Network members. Values of meaningMeth can be-
comenegative as a consequence of repeated negative experiences or interactions: this allows both cessation of
methamphetamineuse and subsequent return touse (should the social environment permit) to be represented
in the simulation.
2.15 Based on these four elements, the overall probability of a user consuming methamphetamine for pleasure
(Cp(x)) is equal to:
Cp(x) = iP ∗ (Stage+ 1) ∗meaningMeth ∗%attempt
2.16 The probability of consumption increases for all users during the weekend (the value of%attempt is added to
Cp) andusers could ‘binge’ according to their stage attribute (Pbinge = Stage∗10). This consumption for plea-
sure is constrained by another attribute, %deterrence (see below), which represents the sum of previous bad
experiences and the probability of the agents revising their decisions to use due to past negative experiences.
JASSS, 19(2) 3, 2016 http://jasss.soc.surrey.ac.uk/19/2/3.html Doi: 10.18564/jasss.3069
Growing tolerance
2.17 The second process of methamphetamine consumption in TreatMethHarm aims to reproduce users’ intensive
consumption ofmethamphetamine. Integrating intensive consumption and growing tolerancewas considered
important given that 62% of the sample recruited into the epidemiological study were classified as dependent
at first interview (Quinn et al. 2013b). We modeled this pattern of methamphetamine use as the interplay be-
tween users’ level of tolerance (stage) and the time spent without consuming methamphetamine (tAbstinent).
2.18 Research suggests that personal characteristics play a role in thepath todependency (Barr et al. 2006; Sussman
& Ames 2008). Although such characteristics such as a person’s biological makeup do not account for the full
range ofmethamphetamine-related behaviours, it is important to represent predispositions to consumption in
ourmodel. In the absence of clear quantification of how these personal characteristics aect consumption, we
integrated these predisposing characteristics [DM1] and their variation across the population by adding an at-
tribute termed personalFactor to each user (randomised normal distribution, µ = 1, σ = 0.4, range [0, 2]). This
attribute modifies the probability of users consuming methamphetamine because of their personal responses
to patterns of intensive use. The final probability to consume due to increased tolerance (Tc(x)) is equal to:
Tc(x) = (Stage+ 1) ∗ personalFactor ∗ tAbstinent.
2.19 Use resulting from tolerance is not subject to the value of meaningMeth, which means that high-stage agents
will consume methamphetamine to relieve withdrawal symptoms despite negative opinions of the drug. The
use sequence in the model first involves users checking their probability to consume for pleasure and, if this is
negative, a check is thenmade to determine a user’s tolerance which can give rise to continued use despite the
user having negative meanings regarding methamphetamine.
2.20 Thepleasure seekingand tolerance-relatedusemotivations combine toproduce theoverallmethamphetamine
use of individual users and the population as a whole. By repetitively consuming methamphetamine, users
slowly increase their stage, and the potential for harm, due to more frequent use of larger doses of metham-
phetamine. The next subsection describes themain process throughwhichusers can reduce their consumption
and, in turn, their stage in TreatMethHarm.
Individual harm and search for treatment
2.21 So far, the conceptualmodel allows agents to consumemethamphetamine regularly, driven by amix ofmotiva-
tions, depending on their attributes. The consumption of methamphetaminemeans that users gradually build
a tolerance to the drug that induces an increase in both frequency and dosage of use. These increases generate
higher risks of harms as well as higher probability of being arrested. In turn, these outcomes modify agents’
future decisions in a dynamic way. TreatMethHarm reproduces the impact of these negative outcomes through
three main de-escalation processes: health-related deterrence, social sanction from peers and being arrested.
Health-related deterrence
2.22 Methamphetamine use is associated with short- and long-term physical and psychological harms. Metham-
phetamine users reduce their consumption and/or search for treatment when they become aware of the dele-
terious outcomes of their drug use (Quinn et al. 2013a). However, there is little evidence about the degree of
harm that triggers this reaction, meaning that we have accommodated a large range of possible user health ex-
periences related tomethamphetamine in themodel. The following subsection describes how TreatMethHarm
attempts to capture users’ decisions to search for help through a range of four health-related variables.
2.23 In the model, users check their physical/psychological state at the beginning of each time step through a com-
parison of two attributes: initialHealth and currentHealth. InitialHealth is defined at the creation of the agent
and does not vary during the simulation. This initial value is set as the result of a random normal distribution
with µ = 60, σ = 5, and range = 45˘75. Conversely, the currentHealth attribute indicates an agent’s health
value throughout the simulation and could vary within the range 0–75. Users will search for support or treat-
ment if theyperceive a significantdierencebetween these twovalues. This ‘significantdierence’ is calculated
by combining an individual feature with a global variable. The global variable is named health-threshold (range
1–40) and serves to calibrate the model. The individual element is represented by the %health attribute ran-
domly distributed using a normal law distribution (µ = 60, σ = 0.4, range = 0 – 2) as users are created prior
to any simulation. This means that users with a low %health value will search for treatment even if their cur-
rentHealth value is only slightly decreased. Conversely, agents with a high %health value will be less inclined
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to search for treatment. By randomly distributing the %health attribute, we ensure a large range of reactions
that is appropriate given the limited knowledge around the triggers for treatment mentioned above, which
also avoids an unrealistically large movement of agents to treatment services that would arise if they all had
the same attribute values.
2.24 Based on these four components, users will reduce their consumption and/or search for treatment according
to the following condition:
currentHealth < initialHealth−%health ∗ health− threshold
2.25 Therefore, %health ∗ health− threshold fluctuates between 0 and 80.
2.26 The value of currentHealth can vary in two ways. First, currentHealth values diminish each time a user con-
sumesmethamphetamine. Second, if users do not usemethamphetamine for at least one time step, then their
currentHealth value is increased by five at the beginning of the next time step.
2.27 Furthermore, inTreatMethHarm,methamphetamineconsumptionproducesbothshort- and long-termchanges
in the physiology and meanings held by the agents. Research suggests that purity can have a major impact on
methamphetamine-related harm users experience (Scott et al. 2015) . In the short term, each dose of metham-
phetamine diminishes a user’s currentHealth value according to the drug’s degree of purity (range 0–1) and to a
harm-factor (range 0–2). These two variables are set by the modeller: the purity variable aims to represent the
impact of drug potency on the behaviour of users, the harm-factor variable is created to calibrate the model.
Users consume doses equal to their actual stage (stage + 1), which means that a S3 agent will consume four
doses at each time step. Wemodelled currentHealth-related harm in the following way:
currentHealtht1 = currentHealtht0 − ((Stage+ 1) ∗Harm− factor) ∗ epurity
2.28 In addition to the harms regular methamphetamine use may induce, TreatMethHarm includes two patterns of
consumption that can influence the production of harm. As constructed in TreatMethHarm (and underpinned
by our epidemiological data), S3 users are inclined to inject the drug. This route of administration confers the
potential for additional harms when compared to others (i.e., snorting, smoking, ingesting), for example, the
risk of blood-borne virus infection (Cros et al. 1999). Hence, the potential physical and psychological harms
associated with injecting methamphetamine are multiplied by two in the simulation. Moreover, and as indi-
cated above, any user that decides to consume could ‘binge’ onmethamphetamine. If so, users consume twice
their stage-related dose, increasing the user’s experiences of methamphetamine-related harms and frequency
of use. The link between injecting and the experience of harms, the values for the consumption of users while
bingeing, and the probability of bingeing were set arbitrarily and need further information to be accurately cal-
ibrated.
2.29 In the long term, repeated self-perceived harms generate a deterrent eect, represented by the %deterrence
attribute (range 0–100). This attribute gradually increases during the simulation. Each time a given user sees
its currentHealth reduced to a value inferior to 10 times its%health value it increases its%deterrence attribute
value by 0.5. A high value of%deterrence prevents users from consuming for pleasure, as described previously.
Influences of peer networks
2.30 In TreatMethHarm, users are subject to peer influence through their interactions with other agents (Bauman
et al. 1992; Ennett & Bauman 1993; Bahr et al. 2005). As indicated earlier, each user belongs to a network com-
posed of an average of five agents. Networks influence their members by modifying their meaningMeth at-
tributes and by assessing if their currentHealth status does not vary toomuch from the average health of other
members.
2.31 If the valueof oneof these twoattributesmoves too far from theaverage valueof thenetwork, a givenuser could
decide to (1) leave this network (it will then join a network with attribute values closer to its own), (2) search for
ways to reducemethamphetamine use, or (3) cease use altogether. In relation to this, our epidemiological data
showed that 30% of the sample who wished to change their use avoided oicial treatment services, and initi-
ated a ‘self-detoxification’ or ‘detox’ periodwith the support of their peers (Quinn et al. 2013a). TreatMethHarm
captures this as a period of abstinence through the self-detox method described below. So, in the model users
will search for treatment or enter into a self-detox period if their currentHealth value is inferior to the mean of
other members’ currentHealthminus the health-threshold:
currentHealth(agent) < XcurrentHealth(network)− health− threshold
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2.32 In themodel,networkmainly influences theusers’meaningMethattribute. Theaccumulatednegativeoutcomes
of networkmembers gradually reduce the averagemeaningMeth value of the network, modifying all members’
meaning-Meth. This change decreases, in turn, the probability for users to consume for pleasure (Cp(x)). Users
re-evaluate theirmeaningMeth attribute regarding methamphetamine once a week.
Being arrested
2.33 In the current implementation of TreatMethHarm it is only perceptions of individual harms and group sanctions
that drive users to seek support or treatment. Other rationales (e.g., maturing out, financial problems, nega-
tive social impacts linked tomethamphetamine use) are not implemented at this stage, as they require further
empirical data. Nevertheless, the epidemiological data suggests that approximately 40% of the initial sample
was arrested in the 12months prior to the survey (Quinn et al. 2013b). To reflect this possibility for users, Treat-
MethHarm includes%arrest, a variable related to the probability of users being arrested (range [0− 100]). The
probability for a given user to be arrested (Pa(x)) depends upon user stage, so the probability of being arrested
is represented as:
Pa(x) = %arrest ∗ (Stage+ 1)
2.34 At the end of any given period, the users have a probability equal to their%deterrence to reduce theirmeaning-
Meth attribute value by 0.2 and increase their%deterrence by 2, in order tomirror the impact of such events on
users’ future choices. Moreover, if arrested, users at a high stage of use are sent to the ‘Prison’ location before
being dispatched to a treatment service. The dierent treatment services are presented below.
Treatment and service interfaces
2.35 To address the second objective of this research, namely to reproduce users’ access to service structures refer-
ring to or providing treatment, TreatMethHarmdisplays a set of ‘locations’ to represent potential paths of users
searching for treatment. This section presents the features of the dierent interfaces and describes how users
interact with them.
2.36 TreatMethHarm includes nine treatment-related locations: three ‘Referring Services’, the ‘Peers’ location, four
‘Treatment Services’ and one ’Prison’. These dierent options were chosen as a result of discussions between
the modeler and illicit drug epidemiologists/experts in Victoria, in the context of Australia’s current treatment
system and referral processes with a focus on methamphetamine (Quinn et al. 2013a; AIHW 2014). Each treat-
ment service – namely, individual drug counseling (IDC), psychiatric treatment, rehabilitation and detox – has
%success,max-population,%entry and duration attributes. The%success attribute defines the probability that
a user will complete the treatment program and reduce its meaningMeth value; the max-population gives the
maximum number of users that can be treated at the same time step; the%entry represents the probability for
a given user to enter the treatment service; and the duration gives the number of time-steps the given agent
will stay in treatment. The duration of each treatment has been calibrated accordingly to our (unpublished)
epidemiological data, but the values of the three other variables are set arbitrarily and need further research to
set appropriate values. Furthermore, in the actual version of the simulation, each user bears a representation
associated to each form of treatment (i.e. beliefIDC, beliefPsyTreat, beliefDetox, and beliefRehab with a range
equal to [-1, 1]) that constrains user decision regarding treatment. Users with a negative belief valuewill not en-
ter related treatment. Theother locations donot display these attributes; theirmain role is to dispatch theusers
searching for treatment to one of the treatment services described above. The referring services are ‘Gen.Pract’
(GP), ‘Soc.Service’ (social services), and ‘Police’. The agents are dispatched to a treatment service according to
their stage and health. Users can enter a treatment service through three dierent mechanisms: professional
help; self-detox; and be-arrested.
2.37 In the first instance, the user decides to search for professional help and goes through the referring services be-
fore entering a treatment service. Theway users are oriented toward the various treatment services is depicted
in Figure 2. Once in the appropriate service, the user modifies its Treatment attribute by indicating the type of
treatment it is undergoing and its duration (based on the duration attribute of the service). During each time
step spent in treatment, users progressively restore their health and, because they cannot consume, progres-
sively decrease their stage. If the treatment is successful (probability based on the%success of the treatment),
users reduce their meaningMeth by 0.2 and increase their %deterrence value by 2. They will also modify their
perception of the treatment, increasing its value by 0.2. However, if the treatment fails, the dierent attributes
do not change and the belief associated with the treatment (e.g. beliefIDC) is reduced by 0.2. At the moment,
these views about treatment are shared across the networks, which implies that if a given agent experienced a
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negative outcome from a particular service, the belief attached to this treatment will diminish for all members
belonging to the same network. If the user displays a negative view towards the support service, it will refuse
to resume the treatment and will resort instead to ‘self-detox’.
2.38 Users that try to self-detoxwill spend (Stage+ 1) * 7 timesteps (equivalent to7 to28days)withoutusingmetham-
phetamine. Again, this value was set arbitrarily and requires further research for validation. In contrast to the
mechanism for treatment services described above, the probability of success is equal to the agent’s %deter-
rence value plus 15%. This increase of 15% is arbitrary but aims to reflect the fact that the user has ‘consciously’
decided to reduce or stop consumption. As with treatment services, a successful self-detoxification leads to a
reduction of themeaningMeth value and an increase of the%deterrence value.
2.39 Users can be arrested while consuming. The first time this happens for a given user they are moved to the
‘Police’ location. Depending on their arrest record, indexed through an attribute termed mem-arrest, as well
as on the value of their stage andmeaningMeth attributes, userswill be oriented to specific treatment services.
However, if themax-populationof those services is reached, these userswill be sent to the ‘Prison’ interface and
will remain ‘in jail’ for (Stage + 1) ∗ 30 time steps without the possibility to consume methamphetamine. In
the similar manner to arrested users (see above), these agents have a probability to reduce theirmeaningMeth
attribute value and increase their%deterrence score at the end of their detention period.
2.40 This section has presented the core of TreatMethHarm functioning by detailing the evolution of the synthetic
population of methamphetamine users and by describing their potential pathways to search for professional
help. The next section presents the implementation of TreatMethHarm and its calibration.
Implementing and Calibrating TreatMethHarm
3.1 The conceptualmodel was implemented in themulti-agent platformNetLogo (Wilensky 1999) using a variation
of the StarLogo programming language (the global architecture of the model and attributes of the agents are
presented in Figure 7. This platform is widely used by social scientists aiming to reproduce socially complex
systems because of the simplicity of the programming language, the user-friendly interface that includes a spa-
tial environment visualisation, the possibility to directly act on the course of a simulation, and the capacity to
observe outputs by plotting key parameters. The simulation runs on a daily time-step system to acknowledge
the frequency of consumption of high-stagemethamphetamine users. TreatMethHarm oers the possibility to
run simulations with a ‘closed’ or ‘open’ system population: the modeller can choose to observe either a spe-
cific population of agents, or to run the simulationwith the addition of newly generated agents at programmed
intervals. Furthermore, as implemented, TreatMethHarm can be launched with a ‘non-blank’ population. Here
the modeller can recreate a specific population by setting the proportions of users according to their stage at
the simulation outset.
3.2 We first needed to calibrate the behavioural algorithms presented above. The description of the conceptual
model presents a large number of variables, with some based on our epidemiological data and others ran-
domised to favour heterogeneity amongst the users and avoid unrealistically large concurrent changes in the
population. Throughout the construction of TreatMethHarm, we run hundreds of simulations to test themodel
outputs and ponder the eect magnitude of implemented variables. During that process, three of them (at-
tempt, harm-factor and health-threshold) appeared to require particular attention due to their major impact
on the trajectories of TreatMethHarm users. The parameter attempt controls the probability with which users
increase their consumption for pleasure; harm-factor and health-threshold determine the moment when users
will search for help and potentially enter treatment.
3.3 In this study, we used epidemiological data from our baseline and follow-up surveys to calibrate the evolution
of the TreatMethHarm population. The original survey (N = 255) was conducted in Melbourne from January
to October 2010, with the follow-up survey administered 12 months later (n = 201) (for more details, please
refer to Quinn et al. (2013a, 2015)). The initial proportions of agents per stage at t and t+ 1 are based on these
empirical findings and are as follows.
3.4 We also aimed to reproduce the ratio of agents that sought professional help and the number abstinent at
follow-up. Analyses of the follow-updata showed that 42 (21%) of the participants had accesseddrug treatment
(potentially for any drug problem) during the follow-up period, while 22% of the cohort indicated past-month
abstinence at the follow-up interview.
3.5 The calibration scenarios were set with an initial population of 250 agents in a closed system population. Each
scenario was repeated 50 times and each simulation ran for 365 time steps to reproduce the follow-up time
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Figure 2: Treatment pathways of users searching for treatment.
Stage (use per week) t t+365
S0(use < 1time) 15% 54%
S1(5times < use ≤ 1time) 26% 22%
S2(14times < use ≤ 5times) 39% 15%
S3(use ≥ 14times) 20% 9%
Table 1: Proportions of users during the follow-up survey.
Variables Values Tested
Attempt 10, 15, 20, 25, 30
Harm-factor 0.8, 1, 1.2, 1.4
Health-Threshold 10, 15, 20, 25, 30
Table 2: Calibration scenario tested values.
gap. At the end of each simulation, we measured the mean values and standard deviations of the following
output variables: the proportions of users in each stage (S0, S1, S2 and, S3), proportion of users that had sought
treatment, and the proportion of users that were abstinent in the last 30 time steps (i.e., a simulated month).
Our goal was to tune the parameters of the simulation to obtain outputs similar to the empirical data.
3.6 While building the model, we ‘pre-screened’ the reaction of the model by using ‘edge’ values to parameterise
simulations (e.g., using values of 0% or 100%; harm-factor values of 0 or 4; health-threshold values of 0 or 60)
and scaling down these values until the results approximated the observed empirical data. It rapidly appeared
that high values of attempt led to an excessive representation of the S3 agents, while large health-threshold
values increased the number of presentations for treatment and, in turn, the number of S0 agents. Aer these
preliminary tests, we reduced the values to be tested to the following table.
3.7 The remaining parameters were unchanged for these calibration scenarios and were set as follows.
3.8 To acknowledge the changes aecting the Melbourne methamphetamine drug market, we decided to set the
purity parameter to mimic the evolution of the methamphetamine purity during the simulated period. The
purity ofmethamphetaminewas gradually increased by 2.5%permonth to reproduce the changes inmetham-
phetamine seizure purity observed in Victoria over the years 2008-2013 (Scott et al. 2015) from 15% to 45%.
The remaining variables were set arbitrarily and require additional research for accurate parameterisation (see
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Parameter Value Parameter Value
%success-IDC 66% %entry-IDC 66%
%success-PsyTreat 66% %entry-PsyTreat 66%
%success-Rehab 66% %entry-Rehab 66%
%success-Detox 66% %entry-Detox 66%
Max-pop-IDC 50 Duration-IDC 70
Max-pop-PsyTreat 50 Duration-PsyTreat 60
Max-pop-Rehab 50 Duration-Rehab 70
Max-pop-Detox 50 Duration-Detox 70
Purity 0.15 to 0.45 Duration-Peers (Stage+1) x 7
%arrest 1 Duration-Prison (Stage+1) x 30
Deterrence 1
Table 3: TreatMethHarm parameters.
Figure 3: Purity of methamphetamine seized in Victoria 2008-2013 (Scott et al. 2015).
Variables Empirical Simulated
Stage 0 (%) 54 55 (SD 3)
Stage 1 (%) 22 21 (SD 2.5)
Stage 2 (%) 15 16 (SD 2.3)
Stage 3 (%) 9 8 (SD 1.8)
UsedTreatment (%) 21 22 (SD 3.2)
Ex-users (%) 22 19 (SD 3.2)
Table 4: Comparison of empirical and simulated data (Source: Quinn et al. 2013a).
Table 5 in the Appendix for more information concerning the value source and importance of these variables).
3.9 A comparison between TreatMethHarm outputs and empirical data allowed us to designate the scenario with
the best goodness of fit. We found that the following set of values approximated the proportions of users in
each stage observed in the epidemiological data, as well as the number of users that sought treatment and the
number abstinent (i.e., userswith no consumption for the last 30 ticks and currently not in treatment): attempt
15%, health-threshold 15, harm-factor 1.2 (see Table 4 for comparison).
3.10 Based on these values, we ran a base scenario and investigated the evolution of the user population. We used
these values to run 100 replicationsof the simulationwith 250agents over aperiodof 365 time steps (equivalent
to one year).
3.11 Figure 4 displays the evolution of our initial population of users. In the first few weeks, the whole population
of users consumedmethamphetamine regularly, increasing their tolerance to the drug and escalating in stage.
Aer the first month, this trend was inverted and the number of S0 agents increased, while the number of S3
users tended to decline. Aer a period of initial fluctuation, the proportion of users at each of the dierent
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Figure 4: Evolution of stagemembership over time.
Figure 5: Evolution of currentHealth across the population of users.
stages tended to equilibrium and stabilised aer three months (equivalent to 100 time steps). Until the end of
the simulated period, the number of S0 users continued to progressively increase with the number of S1, S2,
and S3 decreasing accordingly.
3.12 These fluctuations in the user population could be explained by observing the evolution of bothmeaningMeth
and currentHealth values over time. Indeed, the movements between stages follow the evolution of the global
health of the agents, shown in Figure 5. The first fewweeksof the simulation sees the averagehealthof theusers
dropmarkedly at several time-points, leading most of the users to either seek professional support or attempt
self-detoxification at these points.
3.13 The recurrence of perceived harms induces a progressive shi in the global perception of the users regarding
methamphetamine. This is illustrated in Figure 6, where the average value ofmeaningMeth steadily decreases
aer the first month.
3.14 This slow but constant deterioration of meaningMeth is the result of the combined eect of the network (i.e.,
detrimental outcomes aecting one agent impacting on the global opinion of the other members) and of the
increased deterrence toward the substance gradually built throughout the consumption of the users (the initial
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Figure 6: Evolution ofmeaningMeth across the population.
global averaged %deterrence is equal to 3% and reaches an average of 60.5% at the end of the simulations).
This diminution in the global meaningMeth value is the main cause of the constant increase in number of S0
agents aer the third month of simulation, as shown in Figure 4.
Discussion
4.1 Our agent-based model, TreatMethHarm, simulates the dynamics of methamphetamine use and subsequent
use of treatment services in a virtual population of methamphetamine users. To the best of our knowledge,
TreatMethHarm is the first simulation that mimics the trajectory of methamphetamine users and their access
to treatment services. It is based on a range of variables aiming to reproduce characteristics of real users, such
as growing tolerance, frequency/quantity of use and decisions, as well as network interactions and influence,
and particularities of treatment settings. By combining these dierent components, we attempted to recreate
the complexity inherent tomethamphetamine use and to integrate access to treatment in the ‘careers’ of these
users. The three core mechanisms of TreatMethHarm – the decision to consume (both for pleasure and due
to growing tolerance), the decision to seek help, and treatment pathways – were detailed and combined to
shape the trajectory of virtual agents. By using the right combination of parameters, we were able to generate
proportions of users similar to the data collected during our empirical survey. Furthermore, by establishing a
dialogue between researchers and modellers (Moore et al. 2009), and using the formal integrative tool of the
model itself, we were able to identify gaps in the available literature and the limitations of the model. Future
work needs to investigate these missing data to refine and complete TreatMethHarm. Indeed, the ‘abductive’
process (Agar 2005) underpinning the core functioningof this agent-basedmodel allows researchers to reshape
behavioural algorithms andmodify key parameters as new information and conceptual understanding arises.
4.2 In its current iteration, TreatMethHarm has several limitations. The aggregated harms arising from the use of
multiple drugs during the specified time period are not implemented despite their potential influence on both
physical and psychological states of methamphetamine users. Moreover, the questions of the financial burden
of such use aswell as the availability ofmethamphetamine are not addressed in themodel, as they require spe-
cific data ondrug acquisition. Thegeographical dimension, in termsof distance and remoteness betweenusers’
living places and treatment services, is also absent from the model. Furthermore, during the development of
themodel, themeaningsofmethamphetamineusersabout thedierent supportand treatment servicesappear
pivotal to the decisions of the users. We implemented this by assuming that opinions regarding each service
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would vary according to the success of the treatment, and randomly distributed the treatment-related belief in
order to palliate the lack of information regarding the initial representations and to integrate dierences exist-
ing between ‘service-avoiders’ and ‘service-inclined’ (Quinn et al. 2013a). Nevertheless, further work is needed
to collect information about how treatment services are viewed by service consumers, both initially as well as
how they evolve during a drug use career. Similarly, it would also be useful to understand how usersmanage
risks associated with use of the drug (including the extent of ‘risk denial’) that underpins not only decisions to
use, but also decisions to avoid support services (Peretti-Watel 2003).
4.3 At this stage of its implementation, TreatMethHarm has been verified (i.e., debugged and calculation verified)
and calibrated. Once the simulation has been developed further with better-informed values, we will move to
further validate the model. However, such validation requires comparing simulated outputs with real-world
data. In this context, there are few prospective studies of methamphetamine use, particularly outside of treat-
ment service settings (Quinn et al. 2013a), meaning that further data collection on the trajectories of metham-
phetamine use in the community are required, which limits the actual capacity of TreatMethHarm to evaluate
treatment strategies.
Conclusions
5.1 TreatMethHarm is an agent-based simulation that reproduces the trajectories of methamphetamine userswith
respect to their drug consumption and their experience of treatment services. Methamphetamine use and any
related treatment utilisation is complex and results from the interplay of several key factors. Our model at-
tempts to encompass these various factors by integrating diverse sources of data and best estimates. It is able
to reproduce empirical data accurately but also highlightsmajor gaps in knowledge aroundmethamphetamine
treatment in particular, and how users respond to meanings and harm, that need further research. In con-
clusion, TreatMethHarm is amediator model, aiming to increase the knowledge concerning one specific phe-
nomenon and oer a formal representation of a complex phenomenon (Heath et al. 2009). The next step of this
project will consist of collecting and inserting the aforementionedmissing data and recalibrating themodel to
validate it, once similar data, independent from our research, is available.
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Appendix
Variables Degree of criticality Source
%entry-IDC Low Arbitrary
%entry-PsyTreat Low Arbitrary
>%entry-Rehab Low Arbitrary
>%entry-Detox Low Arbitrary
>Duration-Peers Low Arbitrary
Duration-Prison Low Arbitrary
Duration-IDC Low Empirical
Duration-PsyTreat Low Empirical
Duration-Rehab Low Empirical
%success-IDC Moderate Arbitrary
%success-PsyTreat Moderate Arbitrary
%success-Rehab Moderate Arbitrary
%success-Detox Moderate Arbitrary
Max-pop-IDC Moderate Arbitrary
Max-pop-PsyTreat Moderate Arbitrary
Max-pop-Rehab Moderate Arbitrary
Max-pop-Detox Moderate Arbitrary
%arrest Moderate Arbitrary
Deterrence Moderate Arbitrary
Attempt Critical Calibrated
Table 5: List of TreatMethHarm variables with their value sources and importance.
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Figure 7: Class Diagram of TreatMethHarm.
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